Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a positive trajectory in its diagnostics business, as evidenced by an increase in EsoGuard tests processed, rising from 2,756 in Q2 to 2,841 in Q3, indicating a growing demand for its products. The company's valuation appears attractive, reflecting a balance between high risks and substantial upside potential, particularly as it advances its innovations in medical technology. With the ongoing commercialization of its products, expected significant growth is projected for 2025 and 2026, enhancing the overall outlook for the company's future performance.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million for the quarter, reflecting weakness in expected earnings per share compared to both internal and consensus estimates, which indicates underlying financial challenges. The company also experienced a decline in EsoGuard test volume, processing only 2,756 tests in Q2, down from previous quarters, which raises concerns about demand and operational efficiency. Additional risks include liquidity issues, the potential failure of products in clinical trials, difficulties in gaining regulatory approvals, and challenges in commercialization, all of which could impede future growth and investor confidence.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.